A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This ...
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...
Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...
Molecule is claimed to be made from "natural ingredients" such as dandelion root and fennel seed, but investigations tell a ...
Gabapentin has become the 5th most prescribed drug. It's also getting a bad reputation. Here's why it doesn't deserve it, ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ® (pegvaliase-pqpz) supplemental ...
Parents and clinicians are urged to review usage of certain health products for young children after federal authorities ...
11hon MSN
The Inflammation Gap
Popular ideas about inflammation have lost touch with medical reality.
People with prediabetes experience impaired insulin release and insulin resistance, explained Priya Jaisinghani, M.D., an ...
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback